vs
Orthofix Medical Inc.（OFIX）与PARK NATIONAL CORP（PRK）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是PARK NATIONAL CORP的1.3倍（$219.9M vs $168.3M），PARK NATIONAL CORP净利率更高（25.3% vs -1.0%，领先26.4%），PARK NATIONAL CORP同比增速更快（2.2% vs 2.0%），PARK NATIONAL CORP自由现金流更多（$191.9M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 4.9%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
国家零售系统公司（NRS）旗下包含基石货运公司与国家零售运输公司，是一家成立于1952年的资产型第三方物流服务商，总部位于美国新泽西州林德赫斯特，为客户提供专业的物流供应链相关解决方案。
OFIX vs PRK — 直观对比
营收规模更大
OFIX
是对方的1.3倍
$168.3M
营收增速更快
PRK
高出0.2%
2.0%
净利率更高
PRK
高出26.4%
-1.0%
自由现金流更多
PRK
多$175.1M
$16.8M
两年增速更快
OFIX
近两年复合增速
4.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $168.3M |
| 净利润 | $-2.2M | $42.6M |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | — |
| 净利率 | -1.0% | 25.3% |
| 营收同比 | 2.0% | 2.2% |
| 净利润同比 | 92.4% | 10.4% |
| 每股收益（稀释后） | $-0.05 | $2.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXPRK
| Q4 25 | $219.9M | $168.3M | ||
| Q3 25 | $205.6M | $169.5M | ||
| Q2 25 | $203.1M | $168.7M | ||
| Q1 25 | $193.6M | $157.9M | ||
| Q4 24 | $215.7M | $164.7M | ||
| Q3 24 | $196.6M | $170.3M | ||
| Q2 24 | $198.6M | $157.7M | ||
| Q1 24 | $188.6M | $152.8M |
净利润OFIXPRK
| Q4 25 | $-2.2M | $42.6M | ||
| Q3 25 | $-22.8M | $47.2M | ||
| Q2 25 | $-14.1M | $48.1M | ||
| Q1 25 | $-53.1M | $42.2M | ||
| Q4 24 | $-29.1M | $38.6M | ||
| Q3 24 | $-27.4M | $38.2M | ||
| Q2 24 | $-33.4M | $39.4M | ||
| Q1 24 | $-36.0M | $35.2M |
毛利率OFIXPRK
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — | ||
| Q1 24 | 67.5% | — |
营业利润率OFIXPRK
| Q4 25 | 0.2% | — | ||
| Q3 25 | -8.3% | 34.3% | ||
| Q2 25 | -7.9% | 35.2% | ||
| Q1 25 | -25.2% | 32.4% | ||
| Q4 24 | -5.3% | — | ||
| Q3 24 | -9.6% | 27.4% | ||
| Q2 24 | -12.5% | 30.6% | ||
| Q1 24 | -15.6% | 27.8% |
净利率OFIXPRK
| Q4 25 | -1.0% | 25.3% | ||
| Q3 25 | -11.1% | 27.8% | ||
| Q2 25 | -6.9% | 28.5% | ||
| Q1 25 | -27.4% | 26.7% | ||
| Q4 24 | -13.5% | 23.5% | ||
| Q3 24 | -13.9% | 22.4% | ||
| Q2 24 | -16.8% | 25.0% | ||
| Q1 24 | -19.1% | 23.0% |
每股收益（稀释后）OFIXPRK
| Q4 25 | $-0.05 | $2.62 | ||
| Q3 25 | $-0.57 | $2.92 | ||
| Q2 25 | $-0.36 | $2.97 | ||
| Q1 25 | $-1.35 | $2.60 | ||
| Q4 24 | $-0.76 | $2.38 | ||
| Q3 24 | $-0.71 | $2.35 | ||
| Q2 24 | $-0.88 | $2.42 | ||
| Q1 24 | $-0.95 | $2.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $233.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $1.4B |
| 总资产 | $850.6M | $9.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXPRK
| Q4 25 | $82.0M | $233.5M | ||
| Q3 25 | $62.9M | $218.9M | ||
| Q2 25 | $65.6M | $193.1M | ||
| Q1 25 | $58.0M | $237.6M | ||
| Q4 24 | $83.2M | $160.6M | ||
| Q3 24 | $30.1M | $201.7M | ||
| Q2 24 | $26.4M | $261.5M | ||
| Q1 24 | $27.0M | $306.1M |
总债务OFIXPRK
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXPRK
| Q4 25 | $450.0M | $1.4B | ||
| Q3 25 | $442.5M | $1.3B | ||
| Q2 25 | $458.3M | $1.3B | ||
| Q1 25 | $458.3M | $1.3B | ||
| Q4 24 | $503.1M | $1.2B | ||
| Q3 24 | $525.9M | $1.2B | ||
| Q2 24 | $546.0M | $1.2B | ||
| Q1 24 | $570.3M | $1.2B |
总资产OFIXPRK
| Q4 25 | $850.6M | $9.8B | ||
| Q3 25 | $832.6M | $9.9B | ||
| Q2 25 | $837.2M | $9.9B | ||
| Q1 25 | $823.1M | $9.9B | ||
| Q4 24 | $893.3M | $9.8B | ||
| Q3 24 | $867.9M | $9.9B | ||
| Q2 24 | $882.0M | $9.9B | ||
| Q1 24 | $906.0M | $9.9B |
负债/权益比OFIXPRK
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $198.3M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $191.9M |
| 自由现金流率自由现金流/营收 | 7.6% | 114.1% |
| 资本支出强度资本支出/营收 | 4.9% | 3.8% |
| 现金转化率经营现金流/净利润 | — | 4.65× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $328.2M |
8季度趋势，按日历期对齐
经营现金流OFIXPRK
| Q4 25 | $27.7M | $198.3M | ||
| Q3 25 | $12.4M | $52.6M | ||
| Q2 25 | $11.6M | $49.7M | ||
| Q1 25 | $-18.4M | $37.9M | ||
| Q4 24 | $23.7M | $178.8M | ||
| Q3 24 | $11.7M | $43.8M | ||
| Q2 24 | $9.0M | $50.9M | ||
| Q1 24 | $-18.6M | $35.0M |
自由现金流OFIXPRK
| Q4 25 | $16.8M | $191.9M | ||
| Q3 25 | $2.5M | $51.1M | ||
| Q2 25 | $4.5M | $48.4M | ||
| Q1 25 | $-25.1M | $36.8M | ||
| Q4 24 | $15.2M | $169.7M | ||
| Q3 24 | $6.3M | $41.7M | ||
| Q2 24 | $-360.0K | $49.0M | ||
| Q1 24 | $-29.1M | $31.9M |
自由现金流率OFIXPRK
| Q4 25 | 7.6% | 114.1% | ||
| Q3 25 | 1.2% | 30.1% | ||
| Q2 25 | 2.2% | 28.7% | ||
| Q1 25 | -13.0% | 23.3% | ||
| Q4 24 | 7.0% | 103.0% | ||
| Q3 24 | 3.2% | 24.5% | ||
| Q2 24 | -0.2% | 31.1% | ||
| Q1 24 | -15.4% | 20.8% |
资本支出强度OFIXPRK
| Q4 25 | 4.9% | 3.8% | ||
| Q3 25 | 4.8% | 0.9% | ||
| Q2 25 | 3.5% | 0.8% | ||
| Q1 25 | 3.5% | 0.7% | ||
| Q4 24 | 4.0% | 5.6% | ||
| Q3 24 | 2.7% | 1.2% | ||
| Q2 24 | 4.7% | 1.2% | ||
| Q1 24 | 5.6% | 2.1% |
现金转化率OFIXPRK
| Q4 25 | — | 4.65× | ||
| Q3 25 | — | 1.11× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 0.90× | ||
| Q4 24 | — | 4.63× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.29× | ||
| Q1 24 | — | 0.99× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
PRK
暂无分部数据
